Shandong Weigao Group Medical Polymer Company Limited (01066) disclosed the repurchase of 140,000 H shares on 9 February 2026, conducted on the Hong Kong Stock Exchange at prices ranging from HKD5.25 to HKD5.29. The total amount paid was HKD738,600, bringing the treasury share count from 40,808,400 to 40,948,400.

As a result, the number of issued shares (excluding treasury shares) declined to 4,481,383,924 from 4,481,523,924, representing a 0.0031% decrease. The company’s total issued shares remained at 4,522,332,324. According to the repurchase mandate dated 27 May 2025, the maximum number of shares authorized for repurchase is 451,560,392. As of this transaction, approximately 34,300,000 shares in total have been repurchased under the mandate, representing 7.5959% of the number of issued shares (excluding treasury shares) on the mandate date.

A moratorium on new share issuance or treasury share disposal is in effect until 12 March 2026, pursuant to exchange regulations governing a 30-day restriction following a share repurchase.